Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
Author:
Affiliation:
1. Department of Endocrinology, Baylor Endocrine Center Dallas Texas
2. Department of Diabetes, Eli Lilly and Company, Lilly Corporate Center Indianapolis Indiana
3. Department of Statistics, Eli Lilly Deutschland GmbH Bad Homburg Germany
Funder
Eli Lilly and Company
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13822
Reference21 articles.
1. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists
2. The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
3. Treat‐to‐target trials: uses, interpretation and review of concepts
4. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
5. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria;Journal of Diabetes Science and Technology;2022-12-16
2. Use of Retrospective Continuous Glucose Monitoring Data Is Underrated and Underused;Journal of Diabetes Science and Technology;2022-01-19
3. Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy;Diabetes Technology & Therapeutics;2022-01-01
4. Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion;Diabetes Technology & Therapeutics;2021-10-01
5. Continuous Glucose Monitoring (CGM) Is a Tool, Not a Reward: Unjustified Insurance Coverage Criteria Limit Access to CGM;Diabetes Technology & Therapeutics;2021-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3